skin-20230419

0001818093-23-000014.txt : 20230419 0001818093-23-000014.hdr.sgml : 20230419 20230419172251 ACCESSION NUMBER: 0001818093-23-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230419 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230419 DATE AS OF CHANGE: 20230419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Beauty Health Co CENTRAL INDEX KEY: 0001818093 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 851908962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39565 FILM NUMBER: 23830824 BUSINESS ADDRESS: STREET 1: 2165 SPRING STREET CITY: LONG BEACH STATE: CA ZIP: 90806 BUSINESS PHONE: 800-603-4996 MAIL ADDRESS: STREET 1: 2165 SPRING STREET CITY: LONG BEACH STATE: CA ZIP: 90806 FORMER COMPANY: FORMER CONFORMED NAME: Vesper Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200714 8-K 1 skin-20230419.htm 8-K skin-20230419

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 19, 2023

THE BEAUTY HEALTH COMPANY

(Exact name of registrant as specified in its charter)

Delaware

001-39565

85-1908962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2165 Spring Street

Long Beach, CA

(Address of principal executive offices)

90806

(Zip Code)

(800) 603-4996

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Class A Common Stock, par value $0.0001 per share

SKIN

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 19, 2023, The Beauty Health Company (the “Company”) promoted Brad Hauser to the position of Chief Operating Officer of the Company, effective as of April 19, 2023.

Prior to Mr. Hauser’s appointment as Chief Operating Officer, he served as Chief Product Officer of the Company since January 2023, where he oversaw product development, R&D, regulatory and technology, with a focus on continuing to advance the Company’s HydraFacial delivery systems and pioneer innovation. Mr. Hauser brings more than 20 years’ experience in aesthetic device development and marketing. Prior to joining the Company, he served as President and Chief Executive Officer of Soliton within Allergan Aesthetics, an AbbVie company until July 2022. Mr. Hauser served as President and CEO of Soliton, Inc. from November 2020 until it was acquired by Allergan Aesthetics in December 2021. Previously, he served as the Vice President, R&D and General Manager for CoolSculpting at Allergan Pharmaceuticals since ZELTIQ Aesthetics, Inc. was acquired in April 2017. Mr. Hauser served as the Senior Vice President of Research and Development at ZELTIQ Aesthetics, Inc. from January 2017 to April 2017 and as its Vice President of Research and Development from July 2015 to January 2017. Mr. Hauser joined ZELTIQ in December 2013 as Vice President of Product and Clinical Strategy. Prior to joining ZELTIQ, he held multiple roles in the aesthetic industry, including Executive Vice President of Commercial Operations for Cutera, Director of Research and Development at Medicis, and Managing Director of Product and Clinical Marketing at Solta Medical. Mr. Hauser received his Bachelor of Arts in Human Biology from Stanford University.

There are no arrangements or understandings between Mr. Hauser and any other person pursuant to which Mr. Hauser was appointed to serve as the Chief Operating Officer of the Company. There are no family relationships between Mr. Hauser and any of the Company’s directors or executive officers. Mr. Hauser has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

In connection with Mr. Hauser’s promotion to the position of Chief Operating Officer, effective April 19, 2023, Mr. Hauser will: (i) receive an annual base salary of $475,000; (ii) receive a one-time promotional grant of restricted stock units with an aggregate grant date value of $1,050,000 (the “RSU Award”), and performance-based stock units with an aggregate grant date value of $350,000 (the “PSU Award”); (iii) continue to be eligible to participate in and earn a cash performance bonus under the Company’s Annual Incentive Plan (“AIP”), where his annualized at-target bonus will remain at 60% of his base salary, with the actual amount of any award under the AIP to be determined based on achievement of specific levels of performance goals set by the board of directors of the Company (the “Board”); and (iv) remain eligible to receive long-term incentive awards under The Beauty Health 2021 Incentive Award Plan (the “2021 Plan”) for each fiscal year that Mr. Hauser remains employed with the Company, with any such awards to be determined by the compensation committee of the Board. The RSU Award will vest in equal, one-third increments on each of the first three anniversaries of the grant date of April 19, 2023, in each case subject to continued service through the vesting date and certain acceleration rights. The PSU Award will vest at the conclusion of a three-year performance period based upon the achievement of pre-determined performance metrics determined by the Board or compensation committee (as applicable) on the grant date, subject to continued service with the Company through the vesting date.

Mr. Hauser will also participate in The Beauty Health Company Executive Severance Plan (the “Executive Severance Plan”), which provides that upon a termination of his employment without “cause” or for “good reason” (each as defined in the Executive Severance Plan) before or more than 12 months after a “change in control” by the Company (as defined in the 2021 Plan), he will be entitled to: (1) continued payment of his base salary for 12 months following termination, (2) a prorated target annual bonus for the year of termination, and (3) reimbursement of the employer portion of COBRA premium payments, where applicable, for 12 months following termination.

If, within 12 months following the consummation of a “change in control” of the Company, Mr. Hauser’s employment is terminated without “cause” or for “good reason,” he will be entitled to receive the same severance benefits outlined above, along with a cash payment equal to 100% of his target annual bonus for the year of termination.

Any future severance payments and benefits to Mr. Hauser under the Executive Severance Plan will be subject to his execution of a release of claims in favor of the Company. The Executive Severance Plan also includes a Section 280G “best pay” provision, which provides that if any amount received by Mr. Hauser pursuant to the Executive Severance Plan or otherwise that would be subject to the excise tax imposed by Section 4999 of the Code, Mr. Hauser will be entitled to receive the full amount of the payments and benefits or an amount reduced so that no portion would be subject to the excise tax, whichever would result in the largest payment to Mr. Hauser on an after-tax basis.

The description of Mr. Hauser’s compensation is qualified in its entirety by reference to his promotion offer letter, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosures

On April 19, 2023, the Company issued a press release announcing the promotion of Mr. Hauser as the Company’s Chief Operating Officer, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.						Description
10.1						Promotion Offer Letter, dated April 7, 2023
99.1						Press Release, dated April 19, 2023
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 19, 2023

The Beauty Health Company

By:

/s/ Liyuan Woo

Name:

Liyuan Woo

Title:

Chief Financial Officer

EX-10.1 2 axex101hauserpromotionlett.htm EX-10.1 Document

Exhibit 10.1

April 7, 2023

Dear Brad,

Congratulations on your promotion to your new role as Chief Operating Officer! In this role you will continue to report directly to me and will remain a member of the executive committee.

Based on your promotion, the Board of Directors has approved your new annual salary of $475,000. This amount, less applicable withholdings and deductions will be effective April 19, 2023.

You will continue to be eligible to participate in, and earn a cash performance bonus under, the Corporate Annual Incentive Plan ("AIP") where your annualized at-target bonus will remain at 60% of your base salary. The actual amount of any AIP will be determined based on achievement of specified levels of performance goals set by the Company's Board of Directors. The AIP may be amended or changed from time to time. Any annual incentive that becomes payable will be paid at such time(s) as annual incentives are generally paid to senior executives, subject to your continued employment with the Company through the applicable payment date.

The Board of Directors has also approved a one-time promotional long-term incentive award ("Award") in the amount of $1,400,000. This Award will be granted on April 19, 2023 and will be weighted 75% restricted stock units ($1,050,000) and 25% performance-based stock units ($350,000). This Award will be subject to the terms and conditions of The Beauty Health Company 2021 Incentive Award plan, subject to and contingent upon the approval of the Incentive Plan by the Board and the stockholders of the Company, or any successor plan, and an Award agreement entered between you and the Company.

You will also remain eligible to receive one or more grants of long-term incentive awards for each fiscal year of employment with the Company. The amount (if any), type, and terms and conditions (including vesting conditions) of any such Award shall be determined by the Compensation Committee in its sole discretion.

On behalf of the Board of Directors, I thank you for your efforts and continued dedication to the Company!

Sincerely,

Andrew

2165 East Spring Street, Long Beach, California 90806 beautyhealth.com

EX-99.1 3 axex991sunrisepressrelease.htm EX-99.1 Document

Exhibit 99.1

Maturing into a Multi-Brand Ecosystem, BeautyHealth
Appoints Aesthetics Veteran Brad Hauser as Chief Operating Officer

Newly created role establishes end-to-end product oversight, from innovation to go-to-market

LONG BEACH, Calif.— April 19, 2023 —The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced Brad Hauser’s promotion to Chief Operating Officer (COO), a new position within the company.

Brad will assume end-to-end Operating leadership, overseeing the company’s full product lifecycle, from ideation and innovation to go-to-market. He will continue to lead the existing Product organization, including technology, research and development, quality assurance, and regulatory affairs, and will take on new responsibilities overseeing Operations and Marketing. He will remain a member of the Company’s Executive Committee, reporting to President and Chief Executive Officer Andrew Stanleick.

"Brad is an industry veteran, and since joining BeautyHealth he has demonstrated outstanding leadership, most recently in preparing the business for the international launch of Syndeo, our next generation connected device, which is off to an encouraging start,” said Stanleick. “Positioning Brad to have full line of sight, from concept to market, will enable the Company to move thoughtfully and with speed, especially on our most important initiatives. Brad brings seasoned executive experience and, as COO, will further strengthen our global leadership capabilities as we take advantage of the sizable growth runway ahead.”

Brad joined BeautyHealth in January 2023 as Chief Product Officer. Prior, he led product development, R&D and business integration for top medical device and pharmaceutical companies, including Allergan Aesthetics – an AbbVie Company, Zeltiq Aesthetics, Cutera and Solta Medical. He also served as CEO of Soliton, Inc. during its development of the novel cellulite and tattoo removal medical device RESONIC.

Reflecting on the leadership evolutions, Stanleick said, “BeautyHealth has entered this year focused on launching Syndeo internationally and building further momentum with providers and consumers. These changes allow us to continue to bolster and meet demand for Hydrafacial and the rest of our growing portfolio of brands. I look forward to partnering with Brad in his expanded role, along with the rest of the Executive Committee, to lead the Company into a new era as a true multi-brand ecosystem.”

About The Beauty Health Company

The Beauty Health Company (NASDAQ: SKIN) is a global category-creating company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful community of estheticians, partners and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types in more than 90 countries. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/, and learn more at beautyhealth.com or LinkedIn.

Contacts

The One Nine Three Group

Investors: BeautyHealthIR@the193.com

Press: BeautyHealth@the193.com

EX-101.SCH 4 skin-20230419.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 skin-20230419_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 skin-20230419_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Document Information, Document [Axis] Document Information, Document [Axis] Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Local Phone Number Local Phone Number Document [Domain] Document [Domain] Written Communications Written Communications Cover [Abstract] Document Type Document Type Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 7 skin-20230419_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 19, 2023
Document Information [Line Items]
Document Type	8-K
Document Period End Date	Apr. 19, 2023
Entity Registrant Name	THE BEAUTY HEALTH COMPANY
Entity Address, Address Line One	2165 Spring Street
Entity Incorporation, State or Country Code	DE
Entity File Number	001-39565
Entity Tax Identification Number	85-1908962
Entity Address, City or Town	Long Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90806
City Area Code	800
Local Phone Number	603-4996
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	SKIN
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001818093
Security Exchange Name	NASDAQ

XML 9 skin-20230419_htm.xml IDEA: XBRL DOCUMENT 0001818093 2023-04-19 2023-04-19 false 0001818093 8-K 2023-04-19 THE BEAUTY HEALTH COMPANY DE 001-39565 85-1908962 2165 Spring Street Long Beach CA 90806 800 603-4996 false false false false Class A Common Stock, par value $0.0001 per share SKIN NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://beautyhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports skin-20230419.htm axex101hauserpromotionlett.htm axex991sunrisepressrelease.htm skin-20230419.xsd skin-20230419_def.xml skin-20230419_lab.xml skin-20230419_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "skin-20230419.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "skin-20230419_def.xml" ] }, "inline": { "local": [ "skin-20230419.htm" ] }, "labelLink": { "local": [ "skin-20230419_lab.xml" ] }, "presentationLink": { "local": [ "skin-20230419_pre.xml" ] }, "schema": { "local": [ "skin-20230419.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "skin", "nsuri": "http://beautyhealth.com/20230419", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "skin-20230419.htm", "contextRef": "i3733c93b0f644b1ba0f9a89ecdeaf75e_D20230419-20230419", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://beautyhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "skin-20230419.htm", "contextRef": "i3733c93b0f644b1ba0f9a89ecdeaf75e_D20230419-20230419", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.", "label": "Document [Domain]", "terseLabel": "Document [Domain]" } } }, "localname": "DocumentDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_DocumentInformationDocumentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Document Information, Document [Axis]", "terseLabel": "Document Information, Document [Axis]" } } }, "localname": "DocumentInformationDocumentAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://beautyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001818093-23-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001818093-23-000014-xbrl.zip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